BACKGROUND: Contemporary second-generation drug-eluting stents (DES) have superior efficacy and safety in comparison with early-generation stents in patients undergoing percutaneous coronary intervention, in part, related to their thinner struts. Whether newergeneration ultrathin DES further improve clinical outcomes in comparison with older second-generation thicker strut DES is unknown.
C
ontemporary second-generation drug-eluting stents (DES) have markedly improved outcomes in patients undergoing percutaneous coronary intervention by reducing the risk of restenosis, stent thrombosis, and myocardial infarction (MI), and may improve survival in comparison with bare metal stents and firstgeneration DES. [1] [2] [3] [4] [5] In comparison with first-generation DES, contemporary second-generation DES have thinner struts and more biocompatible polymers, which reduce vascular injury and inflammation, and promote faster endothelialization, decreasing neointimal proliferation and thrombogenicity. 6 Whether event-free survival can be further improved by further enhancements in stent design is uncertain. In comparison with durable polymers, drug elution from bioresorbable polymers and polymer-free systems offers theoretical advantages that, to date, have not been shown to confer improved clinical outcomes. 3, 7 Similarly, outcomes with first-generation bioabsorbable scaffolds have been disappointing. 8 Thus, clinical outcomes with contemporary secondgeneration DES, while outstanding, have plateaued and largely remained steady over the past decade.
Recently, ultrathin strut DES have been introduced with the potential to further reduce vascular injury and accelerate endothelialization. In the BIOFLOW V trial (BiotronikSafety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions), the 60-μm strut thickness Orsiro sirolimus-eluting stent (SES) reduced target lesion failure (TLF) in comparison with a widely used 81-μm strut thickness everolimus-eluting stent (EES). 9 However, this
trial was designed to demonstrate noninferiority and not superiority, and used a Bayesian design to combine data from 2 earlier smaller randomized trials. Thus, whether newer-generation ultrathin strut DES truly improve clinical outcomes in comparison with contemporary thicker strut second-generation DES, and if so, whether such results are confined to the Orsiro stent is uncertain. We therefore sought to evaluate the outcomes with ultrathin strut DES in comparison with current-generation DES, and to examine whether there are meaningful differences between the currently available ultrathin strut DES.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedures. The data are freely available from the published studies.
Study Selection
We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials through December 31, 2017 for randomized clinical trials that compared newer-generation ultrathin strut DES versus older second-generation thicker strut DES and reported clinical outcomes (MeSH search terms in Table I in the online-only Data Supplement). Ultrathin strut was defined as <70-μm strut thickness. The strut thickness cutoff was chosen to have at least a 10 μm lower strut thickness than the thicker strut second-generation DES (strut thickness of ≈81 μm). We checked the reference lists of original trials, other meta-analyses, review articles, and editorials to find other potential eligible trials. There was no language restriction for the search. We also searched the conference proceedings and abstracts of the following societies: American Heart Association, American College of Cardiology, Transcatheter Cardiovascular Therapeutics, Society of Cardiovascular Angiography and Intervention, European Society of Cardiology, and EuroPCR. We kept the search current by setting up automated reminders from PubMed for new publications.
Data Abstraction and Quality Assessment
Two authors (B.T. and N.P.) independently assessed trial eligibility and extracted data. Disagreements were resolved by consensus and by discussion with a third author (S.B.). The 1-year follow-up events from each trial were abstracted. The risk of bias was assessed by using the components recommended by the Cochrane Collaboration 10 : sequence generation of the allocation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Trials with high or unclear risk for bias for any one of the above components were considered at high risk of bias. Otherwise, they were considered at low risk of bias.
Study Outcomes
The primary outcome was TLF defined as a composite of cardiovascular death, target vessel MI, or ischemia-driven
Clinical Perspective
What Is New?
• Data from this meta-analysis of randomized trials indicate that newer-generation ultrathin strut drug-eluting stents (DES) further improve 1-year clinical outcomes in comparison with contemporary thicker strut second-generation DES.
• Ultrathin strut DES reduce the risk of target lesion failure driven by a reduction in myocardial infarction and also a lower rate of stent thrombosis in comparison with contemporary thicker strut second-generation DES.
What Are the Clinical Implications?
• Newer-generation ultrathin strut DES may improve clinical outcomes over contemporary thicker second-generation DES.
• The outcomes with second-generation DES, although outstanding, have plateaued and largely remained steady over the past decade, and further design changes may be warranted to potentially improve outcomes. 
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Statistical Analyses
Data were abstracted from each trial by using results reported in an intention-to-treat approach. Meta-analysis was performed in line with the guidelines from the Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) statement and the recommendations of the Cochrane Collaboration. 10, 11 Fixed continuity correction (addition of 0.5 to each cell) was used for trials with zero events. The meta-analytic summary estimates (relative risk [RR] with 95% CIs) for the newer-generation ultrathin strut DES versus second-generation DES for the above outcomes were calculated by using both the fixed-effect model and the random-effects model of DerSimonian and Laird. 12 This was done to compare the fixed-and random-effects estimates of the intervention effect as recommended by the Cochrane Collaboration given that we anticipated some heterogeneity (I 2 >0). If the estimates are similar, then any small-study effects have little effect on the intervention effect estimate. Heterogeneity was assessed using the I 2 statistic, with I 2 <25% considered low, I 2 ≥25% and ≤75% considered moderate, and I 2 >75% considered high. 13, 14 Small-study effects were assessed by a visual estimate of funnel plot asymmetry and by the regression test of Egger and Begg. Meta-regression analyses were performed to evaluate whether the type of ultrathin strut DES (Orsiro SES versus MiStent SES versus BioMime SES) or the type of comparator (Xience EES versus Resolute Integrity zotarolimus-eluting stent [ZES] versus Nobori biolimus-eluting stent) were an effect modifier for the treatment effect. This was done to evaluate whether the results were consistent across the 3 ultrathin strut DES. Similarly, the meta-regression analysis evaluated whether the type of control stent (which included a wider range of strut thickness [81-120 μm] than the ultrathin stents [60-65 μm]) was an effect modifier. We used residual maximum likelihood to estimate the additive (between-study) component of variance tau 2 for the metaregression analysis. Bootstrap analyses were performed using a Monte Carlo permutation test for meta-regression using 10 000 random permutations. 15 Sensitivity analysis for the primary TLF end point was also performed after excluding the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome VII) in which the control stent was the 120-μm-thick stainless steel Nobori biolimus-eluting stent, in contrast to all other trials in which the control stents were <90-μm-thick cobalt chromium alloy platforms (Xience EES and Resolute ZES). This allowed for the control stents to have a narrow range of strut thickness (81-91 μm). All analyses were performed by using standard statistical software (Stata 14, Stata Corporation) with P<0.05 used to denote statistical significance.
RESULTS
Study Selection and Characteristics of Included Trials
We identified 10 trials that randomly assigned 11 658 patients and which satisfied our inclusion criteria (Figure 1 , Table 1 ).The trials evaluated 3 ultrathin strut DES: Orsiro SES (60 μm) (8 trials, 5444 patients), MiStent SES (64 μm) (1 trial, 703 patients), and BioMime SES (65 μm) (1 trial, 170 patients). The characteristics of the ultrathin strut DES are outlined in Table 2 . The comparators were Xience EES (81 μm) (7 trials, 2782 patients), Resolute Integrity ZES (91 μm) (2 trials, 1295 patients), and the Nobori biolimus-eluting stent (120 μm) (1 trial, 1264 patients). The device and baseline characteristics and bias risk assessments are outlined in Table 1 . The strut thickness of the 3 ultrathin strut DES ranged from 60 to 65 μm, in comparison with the 3 thicker strut control second-generation DES that ranged from 81 to 120 μm.
Target Lesion Failure
In comparison with the older second-generation thicker strut DES, newer-generation ultrathin strut DES were associated with a 16% reduction in TLF (RR, 0.84; 95% CI, 0.72-0.99) (Figure 2A ). Test for subgroup effects based on the ultrathin strut DES type (P=0.58) or based on the comparator DES type (P=0.98) were not significant, suggesting no effect modifications of these variables. Moreover, there was no heterogeneity in the overall analysis nor across the subgroups (I 2 =0), and the test for small-study effects was not significant (no funnel plot asymmetry; Egger P=0.32; Begg P=0.15). Sensitivity analysis was conducted after excluding the SORT OUT VII trial, demonstrating consistent results (RR, 0.84; 95% CI, 0.71-1.00; P=0.057).
The difference in TLF with the newer-generation ultrathin strut DES in comparison with the thicker strut second-generation DES was driven by a lower risk of MI (RR, 0.80; 95% CI, 0.65-0.99) (Figure 2C ), with similar risks of cardiovascular death (RR, 0.91; 95% CI, 0.65-1.27) ( Figure 2B ) and ischemia-driven TLR (RR, 0.97; 95% CI, 0.77-1.22) ( Figure 2D ). Tests for subgroup effects for the 1-year rates of MI, cardiovascular death, and ischemia-driven TLR based on the ultrathin strut DES type (P=0.96, 0.26, and 0.56, respectively) and comparator DES type (P=0.70, 0.88, and 0.17, respectively) were not significant. Moreover, there was no or low heterogeneity (I 2 =0%-16.6%) in the overall analysis and across the subgroups, and the test for small-study effects was not significant (no funnel plot asymmetry; Egger P=0.60, 0.13, and 0.58, respectively).
Stent Thrombosis
Newer-generation ultrathin strut DES were associated with qualitatively lower rates of any (definite, probable, or possible) stent thrombosis (RR, 0.72; 95% CI, 0.51-1.01) ( Figure 3A) and definite or prob- able stent thrombosis (RR, 0.74; 95% CI, 0.53-1.05) ( Figure 3B ) in comparison with the thicker strut second-generation DES. The point estimate for definite stent thrombosis also favored ultrathin strut DES (Figure 3C) . Tests for subgroup effects for any, definite/ probable, and definite stent thrombosis based on the ultrathin strut DES type (P=0.92, 0.91, and 0.58, respectively) and comparator DES type (P=0.39, 0.11, and 0.20, respectively) were not significant. Moreover, there was no heterogeneity (I 2 =0%) in the overall analysis or across the subgroups, and the test for small-study effects was not significant (no funnel plot asymmetry; Egger P=0.83, 0.95, and 1.00, respectively).
DISCUSSION
In the present systematic meta-analysis of data from 10 randomized clinical trials with >11 500 patients, the risk of TLF was reduced with the newer-genera- 
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tion ultrathin strut DES in comparison with the older second-generation thicker strut DES, with lower rates of MI and qualitatively lower rates of stent thrombosis. There were no significant differences in cardiovascular death or ischemia-driven TLR between the stent types. Although the majority of the trials assessed the ultrathin strut Orsiro SES versus Xience EES, tests for subgroup effects showed no effect modulation based on either the type of ultrathin strut DES or the comparator DES used.
Strut Thickness and Outcomes
First-generation DES were formulated from stainless steel and required thick struts (strut thicknesses 132 μm for Taxus Express and 140 μm for Cypher BX Velocity) for adequate radial strength and radio-opacity. Second-generation DES (such as Xience EES, Promus EES, and Resolute ZES) use alloys such as cobalt chromium, platinum chromium, or cobalt nickel that permit thinner struts (80-90 μm) with preserved radial strength and radio-opacity. Numerous clinical trials, registries, ORIGINAL RESEARCH ARTICLE and meta-analyses have shown improved outcomes with these second-generation DES in comparison with first-generation DES or bare metal stents. [1] [2] [3] 5, 7, 25 Thinner struts afford not only greater flexibility and, hence, greater deliverability, but also reduce stent-induced arterial injury and inflammation and facilitate faster endothelialization. 6 Moreover, thinner struts cause less turbulence and areas of low shear than otherwise identical thicker strut stents, with decreased thrombogenicity. 6 To attempt to further improve on the outcomes of durable polymer-based second-generation DES, various iterations have been developed, including bioresorbable polymer-based DES, polymer-free DES, and bioresorbable scaffolds. However, the clinical outcomes with these newer systems have at best been noninferior to their durable polymer counterparts. For example, a number of randomized trials and meta-analyses have shown that the bioresorbable polymer-based non-ultrathin stents are at best noninferior to second-generation durable polymer stents, without evidence of superiority. 3, 7, 8 As such, clinical outcomes have plateaued since the widespread adoption of second-generation DES. More recently, ultrathin strut DES have been introduced. Clinical outcomes from randomized trials comparing these newer devices with contemporary second-generation DES are to date available only for 3 ultrathin strut stents: the Orsiro SES (60-μm strut thickness), the MiStent SES (64-μm strut thickness), and the BioMime SES (65-µm strut thickness). The largest of these studies, the BIOFLOW V trial, reported that Orsiro SES was superior at reducing TLF in comparison with the Xience EES, driven by differences in target vessel MI. 9 Similarly, in the meriT-V trial (BioMime Vs. Xience Randomised Control Clinical Study), the BioMime ultrathin strut DES had a significantly lower risk of MI (0.6% versus 4.8%; P=0.03) in comparison with the XIENCE EES. The present analysis of 10 randomized clinical trials reinforces this result, demonstrating a significant reduction in TLF driven by lower rates of MI with ultrathin strut DES in comparison with secondgeneration DES. The 16% summary estimate relative risk reduction in TLF, although modest, is consistent with what might be expected with a reduction in strut thickness by ≈10 μm. Although the present data set does not allow differentiation of the cause of the lower MI rate with ultrathin DES, it is most likely attributable to the lower stent thrombosis rate observed, and potentially fewer cases of periprocedural MI attributable to less side branch coverage. 6, 26 Of note, there was no difference in TLR between the stents. This is not surprising because prior trials with these stents showed similar angiographic late lumen loss, the driver for TLR. 27 For example, late lumen loss in the PRISON IV trial (Primary Stenting of Occluded Native Coronary Arteries) was 0.12±0.59 mm for the Orsiro SES and 0.07±0.46 mm for the XIENCE EES stent (P=0.52). 23 Similarly, in the meriT-V trial, the BioMime SES and XIENCE EES had nearly identical degrees of in-stent late lumen loss (0.15±0.27 mm versus 0.15±0.29 mm, respectively; P=0.87). 21 In the DESSOLVE II trial (Clinical Investigation of the MiStent Drug Eluting Stent [DES] in Coronary Artery Disease), MiStent SES was superior to 
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fast-release ZES (Endeavor) for 9-month in-stent late lumen loss (0.27±0.46 versus 0.58±0.41; P<0.001). Thinner struts may have less radial force than thicker strut stents. However, the above angiographic outcomes for the ultrathin strut DES are reassuring. Despite this, ultrathin strut DES may not be suitable for lesion subsets underrepresented in these trials, such as heavily calcified lesions, ostial lesions, and chronic total occlusions. The 3 ultrathin strut DES evaluated in the current analysis all elute sirolimus from a bioresorbable polymer. The extent to which differences in drug type (sirolimus versus other limus) or polymer type or composition (bioresorbable polymer versus durable polymer) may have contributed to the superiority of these stents may be questioned. The Orsiro stent that was used in 8 of 10 trials included in this analysis has a bioabsorbable polymer that completely degrades during a period of 12 to 24 months. Thus, the reported 1-year outcome in the present report is at a time point before the polymer completely dissolves, suggesting that it was not the bioresorbable polymer that was responsible for the superior outcomes. Moreover, prior trials and meta-analyses have not shown improved clinical outcomes with non-ultrathin bioabsorbable polymers in comparison with durable polymers. 3, 7 Nor have prior trials shown superiority of sirolimus-eluting first-generation (Cypher) DES in comparison with the second-generation DES. Many non-ultrathin bioresorbable polymer-based DES also elute sirolimus. Yet, as discussed above, these stents were not shown to be superior to durable polymerbased second-generation stents eluting other limusanalogue agents. As such, the results in the current analysis are unlikely to be explained by the polymer composition or by the drug eluted. Of note, no significant differences in 1-year outcomes were apparent between the 74-μm bioabsorbable polymer-based everolimus-eluting SYNERGY stent and the 82-μm durable polymer-based everolimus-eluting XIENCE stent in a large randomized trial. 28 Thus, as long as the polymer is biocompatible and causes low inflammation, its permanence may be less important than strut thickness in determining safety outcomes, and, in this regard, >10 μm reduction in strut thickness from the prior standard may be required to obtain a clinically relevant improvement.
Study Limitations
We did not have access to individual patient data from the component studies in the present report. As such, multivariable analyses and subgroup analyses were not possible, and we cannot account for small differences in baseline characteristics between the groups. However, statistical heterogeneity was low to absent in most of the analyses, indicating consistency in effect across trials. Nonetheless, individual patient data might help determine, for example, whether the benefit of ultrathin strut devices is restricted to or particularly evident in certain lesion types, such as bifurcations or small vessels. Although the meta-regression analysis for subgroup effect did not show a difference based on type of ultrathin or control stent used, the results were largely driven by the Orsiro stent versus the Xience comparator (although the results for Orsiro stent by itself was not statistically significant). Whether the results extend to the other ultrathin stents needs to be evaluated in trials powered for clinical outcomes. The CIs around the RRs for the TLF and MI treatment effects were wide, and the observed differences between devices in stent thrombosis did not strictly reach statistical significance. Additional randomized trials would provide greater power to tighten the CIs around the point estimates. Finally, longer-term follow-up is required to examine whether larger differences in MI or stent thrombosis between the device types will emerge over time, and whether the safety advantage of ultrathin strut DES translates into a lower rate of cardiovascular mortality.
Conclusions
In the present systematic meta-analysis of 10 trials in which 11 658 patients were randomly assigned, newergeneration ultrathin strut DES reduced the 1-year risk of TLF in comparison with the contemporary thicker strut, older second-generation DES, driven by less MI and stent thrombosis. Newer-generation ultrathin strut DES thus may represent the next standard in DES technology. Additional studies and longer-term follow-up are needed to confirm these findings and to evaluate the durability of effect.
